Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PT-106 + PT-107 + PT-108 is a combination live biotherapeutic product (LBP) and antioxidant therapy being developed by ProbioTech USA for women's health indications, including bacterial vaginosis (BV) and recurrent urinary tract infections (rUTI). The product utilizes a patented dual-phase delivery technology, administered as a vaginal suppository, which ensures the controlled release of active ingredients. The first phase involves the release of antioxidants to enhance mucosal receptivity and health, while the second phase delivers synergistic live bacteria to correct microbiome imbalances in the urogenital tract. This program is currently in preclinical development in collaboration with the Mayo Clinic and Baylor College of Medicine.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on PT-106 + PT-107 + PT-108.